AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05182112
Drug: Gemcitabine and Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will start cisplatin 10 mg/m2 and gemcitabine 600 mg/m2 intravenously q2 weeks for 1 cycle while undergoing simulation and radiation treatment planning procedures. After completion of CRT, adjuvant cisplatin 25 mg/m2 and gemcitabine 600 mg/m2 q2 weeks will be continued until progression or unacceptable toxicity.
Trial: NCT05523895
Drug: Pimavanserin
RxNorm normalized name: Pimavanserin
DrugBank: Pimavanserin (DB05316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimavanserin
Trial: NCT05039073
Drug: Brentuximab Vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT05805865
Drug: Toothpaste Tablet
RxNorm normalized name: Sodium Fluoride 0.22 g in 100 ORAL PASTE, DENTIFRICE [Dr.NOAH Toothpaste Tablets]
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colgate Anywhere Toothpaste Tablets
Trial: NCT04742205
Drug: Tranexamic Acid 500 MG
RxNorm normalized name: tranexamic acid 500 MG
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loading dose of trial (1g of tranexamic acid in 10ml) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial mixed in 500ml sodium chloride 0.9% is given over 8 hours
Trial: NCT05161780
Drug: Lactated Ringer's Irrigation
RxNorm normalized name: Lactated Ringer'S Irrigation
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactated Ringers at 40C will be used for the entirety of the surgery including the approach and exposure of the tumor as well as tumor resection, After surgery, two blinded skull base surgeon reviewers will rate the clarity of the endoscopic field of view at the recorded intervals. The surgical field will be graded using a widely accepted numeric integer (Boezaart) scale.
Trial: NCT00002269
Drug: Ampligen
DrugBank: Rintatolimod (DB16425)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002269
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05979051
Drug: SHR-1703
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 will be administered by Subcutaneous injection in Phase 2 and Phase 3.
Trial: NCT05976217
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg daily by mouth for 3 weeks This drug inhibits a protein (Bcl-2) that protects cells from undergoing programmed cell death.
Trial: NCT05489523
Drug: Tafamidis 61 MG
RxNorm normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tafamidis 61 mg by mouth daily for 12 months
Trial: NCT06471829
Drug: Lu AG13909
RxNorm normalized name: Lu-DOTA-TATE
DrugBank: Lutetium Lu 177 dotatate (DB13985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution for injection/infusion
Trial: NCT04872790
Drug: Dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT04872790
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT04872790
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05831345
Drug: Methadone Hydrochloride
RxNorm normalized name: Methadone Hydrochloride
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Classic induction of anesthesia (opioid, hypnotic and curare) but the team is blinded to the opioid used (sufentanil or methadone), which is prepared in identical syringes by the pharmacy
Trial: NCT04783675
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab (375 mg/m2) will be given as a single intravenous infusion after remission
Trial: NCT05299931
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dose escalation from every 8 weeks to every 4 weeks only in arm 2
Trial: NCT06523595
Drug: VX-993
RxNorm normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension for Oral Administration.
Trial: NCT06523595
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Tablets for Oral Administration.
Trial: NCT06208215
Drug: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants ≥1 year old who receive SOC therapy and 5 mg/kg of RZ358 or placebo
Trial: NCT06208215
Drug: RZ358 (10 mg/kg) or Placebo + SOC
RxNorm normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants ≥1 year old who receive SOC therapy and 10 mg/kg of RZ358 or placebo
Trial: NCT06208215
Drug: RZ358 (5-10 mg/kg) + SOC
RxNorm normalized name: Immunoglobulin G2, anti-(human insulin receptor) (human monoclonal RZ358 γ2-chain), disulfide with human monoclonal RZ358 κ-chain, dimer
DrugBank: Ersodetug (DB18182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant participants from ≥3 months to \<1 year old who receive SOC therapy + RZ358 starting at 5 mg/kg and increasing to 10 mg/kg of RZ358, as needed, per the protocol schedule
Trial: NCT04932434
Drug: Psilocybin therapy
RxNorm normalized name: Monistat Simple Therapy
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Psilocybin administration session 1: 10mg delivered orally with psychological support and monitoring~* Psilocybin administration session 2: 25mg delivered orally with psychological support and monitoring
Trial: NCT05161598
Drug: Teclistamab
RxNorm normalized name: Teclistamab
DrugBank: Teclistamab (DB16655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teclistamab will be administered subcutaneously (SC).
Trial: NCT05381597
Drug: 5-fluorouracil cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Apply the cream to the size of their lesion extending to the 0.5 cm area of skin surrounding the lesion twice daily for 28 days.
Trial: NCT06250400
Drug: Loratadine 10 Mg
RxNorm normalized name: loratadine 10 MG
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: orally, 10mg once a day for 4 weeks
Trial: NCT04702581
Drug: PCV chemotherapy
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given.
Trial: NCT04702581
Drug: Radiotherapy and PCV chemotherapy
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally
Trial: NCT04800666
Drug: Mecobalamin Tablets
RxNorm normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral Mecobalamin Tablets tid-8
Trial: NCT04149275
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with oral Cabozantinib once daily
Trial: NCT04149275
Drug: Ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration of Ipilimumab on 21 day cycles
Trial: NCT04149275
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV administration of Nivolumab on 21 day cycles, followed by Nivolumab maintenance on 28 day cycles
Trial: NCT05820893
Drug: Resistant Potato Starch
RxNorm normalized name: Potato Starch
DrugBank: Potato (DB10562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MSPrebiotic (MSPrebiotic Inc, Carberry, Manitoba, Canada). MSPrebiotic is an unmodified resistant starch derived from potatoes (Solanar tuberosum). It consists of 20% amylose and 80% amylopectin forming granules the stomach and small intestine are unable to digest allowing for absorption in the colon. MSPrebiotic is consumed by mixing 10g into cold or room temperature foods or beverages; it is not to be heated. Participants will be instructed to take MSPrebiotic 2 or more hours before or after consuming any medications.
Trial: NCT04426968
Drug: Pegylated Interferon
RxNorm normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 180 ug/week subcutaneously (s.c.) for 28 week
Trial: NCT06427005
Drug: Fruquintinib
RxNorm normalized name: fruquintinib
DrugBank: Fruquintinib (DB11679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fruquintinib 5 mg daily for 14 days followed by a 7-day break
Trial: NCT06427005
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: S-1 80-120 mg daily for 14 days, followed by a 7-day break
Trial: NCT06427005
Drug: raltitrexed
RxNorm normalized name: raltitrexed
DrugBank: Raltitrexed (DB00293)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: raltitrexed 3 mg/m² on day 1, with a maximum dose of 5 mg
Trial: NCT06416111
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bupivacaine is a potent local anesthetic with unique characteristics from the amide group of local anesthetics.
Trial: NCT06416111
Drug: Prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prilocaine is an amide local anesthetic secondary amine with an intermediate length of duration and quick onset of action.
Trial: NCT05564611
Drug: Omalizumab 150mg
RxNorm normalized name: OMALIZUMAB 150MG/VIL INJ
DrugBank: Omalizumab (DB00043)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of 150 mg lyophilized vial will be administered in the upper arm as the site of injection
Trial: NCT06800274
Drug: azelastine hydrochloride 0.05%
RxNorm normalized name: Azelastine Hydrochloride 0.05% Ophthalmic Solution
DrugBank: Azelastine (DB00972)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 54 patients were randomly assigned to azelastine hydrochloride 0.05% instilled as 1 drop per eye 2 times a day in the conjunctival sac for for four weeks. Specific diagnostic tests and procedures for dry eye disease were performed at week 0 (baseline), week 2 and week 4.
Trial: NCT06189209
Drug: Tenalisib
RxNorm normalized name: Tenalisib
DrugBank: Tenalisib (DB15295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenalisib will be administered 800mg/ 400mg BID, orally
Trial: NCT05512390
Drug: ABBV-319
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV); Infusion
Trial: NCT06206291
Drug: Cannabidiol (CBD) 200mg
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: First 4 weeks: CBD (200mg)/Placebo twice daily adjunct with opioid agonist treatment.
Trial: NCT06206291
Drug: Cannabidiol (CBD) 400mg
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Second 4 weeks: All cohorts receive CBD (400mg) twice daily adjunct with opioid agonist treatment.
Trial: NCT05858515
Drug: Baricitinib 4 MG
RxNorm normalized name: baricitinib 4 MG
DrugBank: Baricitinib (DB11817)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nonproprietary name: Baricitinib
Trial: NCT05578001
Drug: Pilocarpine Ophthalmic
RxNorm normalized name: pilocarpine ophthalmic
DrugBank: Pilocarpine (DB01085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 drop of Pilocarpine 1%
Trial: NCT05904119
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Lomustine
Trial: NCT06021197
Drug: NMDAE
RxNorm normalized name: NMDA
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Use of an NMDA enhancer for the treatment of CIAS
Trial: NCT05857384
Drug: Acetazolamide 250 MG
RxNorm normalized name: acetazolamide 250 MG
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A solid tablet containing 250 mg acetazolamide
Trial: NCT05857384
Drug: Dronabinol 2.5 MG
RxNorm normalized name: dronabinol 2.5 MG
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A soft gelatin capsules containing 2.5mg dronabinol
Trial: NCT05955508
Drug: Linvoseltamab
RxNorm normalized name: Linvoseltamab
DrugBank: Linvoseltamab (DB17447)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration by intravenous (IV) infusion
Trial: NCT05391061
Drug: Abrocitinib
RxNorm normalized name: Abrocitinib
DrugBank: Abrocitinib (DB14973)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets
Trial: NCT05374525
Drug: APRETUDE
RxNorm normalized name: Apretude
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Available as intramuscular injection.
Trial: NCT05374525
Drug: Cabotegravir OLI
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Available as marketed orally administered tablets.
Trial: NCT05888870
Drug: SCT800 and Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: SCT800 50IU/kg TIW alone or treated with Daratumumab 8mg/kg 4-8 times
Trial: NCT05888870
Drug: SCT800
RxNorm normalized name: 1-740-BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 HEAVY CHAIN) FUSION PROTEIN WITH HUMAN BLOOD COAGULATION FACTOR VIII B DOMAIN FRAGMENT (14-AMINO ACID LINKER) FUSION PROTEIN WITH BLOOD COAGULATION FACTOR VIII (RECOMBINANT HUMAN SCT800 LIGHT
DrugBank: Omfiloctocog alfa (DB19229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT800 50IU/kg TIW alone
Trial: NCT06119581
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IV.
Trial: NCT06119581
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT06119581
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered IV.
Trial: NCT06119581
Drug: Pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered IV.
Trial: NCT04507178
Drug: Nadroparin Injectable Product
RxNorm normalized name: nadroparin Injectable Product
DrugBank: Nadroparin (DB08813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: high dose LMWH compared to prophylactic dose LMWH
Trial: NCT06279221
Drug: LITFULO
RxNorm normalized name: Litfulo
DrugBank: Ritlecitinib (DB14924)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as provided in real world practice
Trial: NCT05650775
Drug: Concerta
RxNorm normalized name: Concerta
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-week trial of oral methylphenidate extended release
Trial: NCT05650775
Drug: Adderall-XR
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-week trial of oral mixed amphetamine salts, extended release, administered only to children who do not show at least 30% improvement during the Concerta/Methylphenidate trial.
Trial: NCT06051045
Drug: Bulevirtide
RxNorm normalized name: Bulevirtide
DrugBank: Bulevirtide (DB15248)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Hepcludex, 2 mg daily subcutaneous injection
Trial: NCT06564389
Drug: PF-07832837
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: escalated doses of PF-07832837
Trial: NCT04284787
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV or SC
Trial: NCT05117632
Drug: ALTO-100 PO tablet
RxNorm normalized name: Altoprev
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one tablet twice daily
Trial: NCT06111547
Drug: TAK-279
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-279 oral tablet.
Trial: NCT06604624
Drug: semaglutide
RxNorm normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: semaglutide ，0.25mg/0.5mg/1.0mg/1.7mg/2.4mg，SC，once a week
Trial: NCT04284787
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT06425055
Drug: Vonafexor
RxNorm normalized name: Vonafexor
DrugBank: Vonafexor (DB18782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * One tablet of a low dose of vonafexor QD from Day 1 to Week 4~* One tablet of a medium dose of vonafexor QD from Week 5 to Week 8~* One tablet of a high dose of vonafexor QD from Week 9 to Week 24
Trial: NCT06177457
Drug: PF-07293893
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-07293893 will be administered as tablets every day (QD) over 14 days
Trial: NCT06177457
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07293893
Trial: NCT06784076
Drug: Anifrolumab
RxNorm normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Anifrolumab 300mg intravenous infusions administered as described in the EU SmPC
Trial: NCT06548412
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by IV
Trial: NCT06548412
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT06548412
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by IV
Trial: NCT06331845
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m2 on Days 1 and 8
Trial: NCT06331845
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a total of 80-100 mg/m2 for d1-3
Trial: NCT06331845
Drug: Paclitaxel protein-bound
RxNorm normalized name: Paclitaxel Protein-Bound
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 260 mg/m2 on Day 1
Trial: NCT06331845
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg on Day 1
Trial: NCT06798675
Drug: nC-001
RxNorm normalized name: 9-NC
DrugBank: Rubitecan (DB06159)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: solid dosage form single dose
Trial: NCT06799442
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mic dexmedetomidine which is diluted to 2ml.
Trial: NCT06382155
Drug: Vosoritide Injection
RxNorm normalized name: vosoritide Injection
DrugBank: Vosoritide (DB11928)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Experimental Drug Lyophilized powder for reconstitution
Trial: NCT06382155
Drug: Human Growth Hormone
RxNorm normalized name: Human growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Commercial product containing somatotropin
Trial: NCT05820685
Drug: Dronabinol
RxNorm normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants in this arm will get Dronabinol 10 mg in addition to standard of care pain medication as needed for breakthrough pain
Trial: NCT05997485
Drug: Nirmatrelvir/Ritonavir
RxNorm normalized name: NIRMATRELVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid.
Trial: NCT06370195
Drug: Lidocaine hydrochloride
RxNorm normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Trial: NCT06249191
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT06249191
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06249191
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV